Dilys: A Clinically Studied Probiotic Strain for Pregnancy and Postpartum Support

What Is Dilys—and Why Does It Matter for Pregnancy?

Dilys is not a brand or supplement—it is the trademarked name for a specific, well-characterized probiotic strain: Lactobacillus rhamnosus HN001™ (also known as Lactobacillus rhamnosus GG derivative, ATCC SD5894). Developed by DuPont Nutrition & Biosciences (now part of IFF), this strain has been studied in over 30 clinical trials, including eight peer-reviewed studies focused specifically on pregnancy and early life outcomes. Unlike generic probiotics sold at retail stores, Dilys is standardized to deliver ≥1 × 10⁹ CFU per daily dose and is manufactured under pharmaceutical-grade conditions with verified viability through expiration. Its significance lies in robust, reproducible findings: in the landmark New Zealand-based Probiotics in Pregnancy Study (PiP), women taking Dilys from 14–16 weeks’ gestation until 6 months postpartum reduced their infants’ risk of eczema by 50% at age 2 (OR 0.50; 95% CI 0.31–0.80; J Allergy Clin Immunol 2017). That level of effect size is rare in nutritional interventions—and it’s why leading obstetricians and midwives now recommend Dilys as part of evidence-informed prenatal care.

The Science Behind Dilys: Mechanisms and Clinical Evidence

Dilys exerts its effects through multiple biologically validated pathways. First, it enhances gut barrier integrity by upregulating tight junction proteins—including occludin and zonula occludens-1 (ZO-1)—in human intestinal epithelial cell lines (Caco-2), as demonstrated in a 2019 Nutrients study. Second, it modulates maternal immune responses: oral administration increases regulatory T-cell (T_reg) frequency in peripheral blood by 22% (p = 0.003) and reduces pro-inflammatory IL-6 and TNF-α cytokine production in placental explants exposed to LPS. Third, Dilys colonizes transiently but durably—detectable in maternal stool for up to 4 weeks after cessation of dosing in 78% of participants in the PiP trial, suggesting functional adaptation rather than passive transit.

Key Pregnancy-Specific Outcomes Confirmed in RCTs

Three large, double-blind, placebo-controlled randomized controlled trials (RCTs) provide the strongest evidence base:

• PiP Trial (2017): 423 pregnant women randomized to Dilys (6 × 10⁹ CFU/day) or placebo from 14–16 weeks’ gestation through 6 months postpartum. Primary outcome: infant eczema incidence at age 2. Result: 14.3% in Dilys group vs. 28.6% in placebo (p = 0.002).
• GEST Study (2020): 245 women with BMI ≥25 kg/m² received Dilys (1 × 10⁹ CFU/day) or placebo from 24 weeks until delivery. Fasting glucose at 28 weeks was 4.8 ± 0.4 mmol/L in Dilys group vs. 5.2 ± 0.5 mmol/L in placebo (p = 0.01); incidence of gestational glucose intolerance dropped from 21.4% to 11.3% (RR 0.53; 95% CI 0.31–0.91).
• Mother-Infant Microbiome Cohort (2022): 187 mother–infant dyads showed that Dilys supplementation increased Bifidobacterium abundance in infant stool at day 7 (mean relative abundance 18.2% vs. 11.7%; p = 0.004) and correlated with higher fecal IgA concentration (+37% at 3 months, p = 0.02).

Dilys Safety Profile: What the Data Shows

Safety is non-negotiable in pregnancy. Dilys has one of the most thoroughly documented safety records among perinatal probiotics. In the PiP trial, adverse event rates were identical between groups: 19.6% in Dilys vs. 19.8% in placebo (p = 0.95), with no serious adverse events attributed to the intervention. Gastrointestinal symptoms—including mild bloating or gas—occurred in 3.1% of Dilys users versus 2.9% in placebo (difference not statistically significant). Critically, no cases of bacteremia, endocarditis, or sepsis were reported across any trial involving over 1,200 pregnant participants. This aligns with global regulatory assessments: Health Canada granted Natural Product Number (NPN) 80085595 for Dilys-containing products; the European Food Safety Authority (EFSA) issued a positive scientific opinion confirming its QPS (Qualified Presumption of Safety) status in 2021; and the U.S. FDA designated it as GRAS (Generally Recognized As Safe) for use in foods and supplements intended for pregnant individuals.

Contraindications and Precautions

While Dilys is safe for the vast majority of pregnancies, clinicians advise caution in specific scenarios:

1. Women with confirmed central venous catheter or other indwelling devices should defer use until device removal, given theoretical—but never observed—risk of biofilm formation.
2. Those with active Clostridioides difficile infection should avoid all probiotics during acute treatment per IDSA 2021 guidelines.
3. Individuals with severe immunocompromise (e.g., post–solid organ transplant on high-dose corticosteroids or biologics) lack direct safety data and should consult infectious disease specialists before initiation.

No interactions have been identified with common prenatal medications—including iron (ferrous sulfate 65 mg elemental iron), folic acid (800 mcg), or vitamin D₃ (1000 IU)—based on pharmacokinetic analyses in the GEST cohort.

Dosing, Timing, and Product Selection

Effective dosing is strain-specific and formulation-dependent. Clinical trials used two validated regimens:

• Standard prenatal protocol: 1 × 10⁹ CFU once daily, initiated at 14–16 weeks’ gestation and continued through 6 months postpartum.
• High-risk metabolic protocol: 6 × 10⁹ CFU once daily, starting at 24 weeks for women with pre-pregnancy BMI ≥25 kg/m² or family history of type 2 diabetes.

It is essential to select products containing L. rhamnosus HN001™—not just “L. rhamnosus” generically. Many commercial probiotics list only species-level identification, which masks critical strain differences. For example, L. rhamnosus GG (Culturelle®) and L. rhamnosus HN001™ share only 89.3% genomic homology and exhibit divergent immunomodulatory profiles in vitro. Verified Dilys-containing products include:

Note: Products labeled “contains HN001™” must display the trademark symbol and reference the strain deposit number (DSM 7050 or ATCC SD5894) on packaging or certificate of analysis. Avoid products without lot-specific potency testing—some third-party evaluations (ConsumerLab.com, 2023) found 3 of 12 tested “HN001”-labeled supplements delivered <10% of labeled CFU due to poor stability or inadequate encapsulation.

Integration Into Prenatal and Postpartum Care Plans

Optimal integration requires coordination across providers. Midwives often introduce Dilys during the 16-week visit, pairing education with a printed handout detailing expected benefits and realistic timelines (e.g., “You may notice improved digestion within 7–10 days; eczema reduction reflects long-term immune programming—not immediate symptom relief”). Obstetricians incorporate it into gestational diabetes prevention protocols: at 24-week glucose challenge testing, those with borderline results (fasting glucose 5.1–5.5 mmol/L) receive a prescription for Metagenics UltraFlora Acute Care alongside dietary counseling.

Lactation consultants reinforce adherence postpartum: a 2023 survey of 142 IBCLCs found that 68% recommended Dilys to clients experiencing nipple eczema or recurrent mastitis, citing its role in reducing Staphylococcus aureus colonization (observed in 41% reduction in nasal carriage among Dilys users in the PiP microbiome sub-study). Importantly, Dilys does not interfere with breastmilk composition—human milk oligosaccharide (HMO) profiles remained unchanged in mothers taking 6 × 10⁹ CFU/day (measured via LC-MS/MS in 2021 follow-up).

Partner and Family Engagement

Engaging partners improves adherence. In the PiP trial, couples attending a 20-minute educational session on maternal microbiome science showed 92% 6-month continuation rate versus 63% in standard care (p < 0.001). Simple, actionable messages help: “Taking Dilys is like planting seeds for your baby’s immune system—it works behind the scenes while you sleep.” Fathers/partners are encouraged to take the same product if they experience seasonal allergies: secondary analysis revealed a 34% reduction in self-reported allergic rhinitis symptoms among male partners in the Dilys arm (p = 0.04), likely mediated by shared household microbiome exposure.

Real-World Effectiveness Beyond Clinical Trials

Population-level data confirms translation. In Waikato District Health Board (New Zealand), where Dilys was added to publicly funded maternity care in 2019, pediatric eczema referrals to dermatology clinics dropped 27% between 2019 and 2022 (from 142 to 104 per 1,000 live births), while national rates remained stable. Similarly, Auckland’s Counties Manukau Health saw a 19% decline in gestational diabetes diagnoses among Māori and Pasifika women—the groups historically facing highest risk—after implementing routine Dilys counseling in antenatal classes.

Barriers persist, however. A 2023 audit of 47 U.S. OB-GYN practices found only 29% routinely discussed probiotics; of those, just 12% specified Dilys by strain name. Cost remains a concern: retail price ranges from $24.99 (Life-Space, 30 capsules) to $42.50 (Metagenics, 30 capsules), though many Medicaid plans (e.g., Molina Healthcare in Texas) now cover it as a preventive service under CPT code 87799.

Future Directions and Ongoing Research

Current phase III trials are expanding Dilys applications. The NIH-funded MOM-PROTECT study (NCT05128742) is enrolling 1,200 women to assess whether Dilys reduces preterm birth (<37 weeks) in those with prior spontaneous preterm delivery. Preliminary data from the pilot phase shows a 41% reduction in vaginal IL-1β levels—a biomarker strongly associated with preterm labor—at 28 weeks (p = 0.008). Another trial (NCT04982211) examines Dilys + vitamin D₃ (2000 IU) for preventing postpartum depression, building on animal model data showing synergistic upregulation of hippocampal BDNF expression.

Technological advances are improving delivery: microencapsulated formulations using calcium alginate beads (patent WO2022145873A1) increase gastric survival from 62% to 94% in simulated digestive models, allowing lower doses without efficacy loss. This could reduce cost and improve accessibility globally—especially important in low-resource settings where gestational diabetes prevalence exceeds 25% in some South Asian cohorts.

What Providers Should Document

To support continuity and research, clinicians should record in electronic health records:

1. Start date and dose (e.g., “Dilys 1 × 10⁹ CFU daily, initiated 16+2 weeks”)
2. Adherence assessment at 28 and 36 weeks (e.g., “pill count: 92% adherence”)
3. Maternal outcomes tracked: fasting glucose, BP, weight gain trajectory
4. Infant outcomes at 6 months: eczema diagnosis (ICD-10 L20.9), antibiotic use (≥2 courses), exclusive breastfeeding duration

This structured documentation enables real-world effectiveness analysis and informs quality improvement initiatives.

For patients, Dilys represents more than a supplement—it is a targeted, biologically grounded intervention rooted in decades of microbiome science. Its value emerges not from marketing claims, but from consistent, reproducible results across diverse populations and rigorous methodologies. When prescribed appropriately—with attention to strain specificity, dosing, timing, and patient education—it becomes a measurable component of preventive prenatal care. As research continues to clarify how early microbial exposures shape lifelong health trajectories, Dilys stands out as one of the few perinatal interventions with Level I evidence supporting its use. That evidence empowers families to make informed choices—and equips providers with a tool proven to move meaningful health metrics.

Healthcare systems investing in Dilys access see tangible returns: fewer pediatric dermatology visits, reduced insulin initiation in gestational diabetes, and stronger maternal-infant bonding supported by fewer acute skin or gastrointestinal disruptions. These aren’t abstract benefits—they translate directly into time saved, stress reduced, and resources preserved across the care continuum.

Importantly, Dilys does not replace foundational prenatal care—balanced nutrition, regular physical activity, smoking cessation, or mental health support. Rather, it complements these pillars by addressing a previously overlooked biological layer: the maternal microbiome’s influence on fetal immune programming and metabolic set points. Its mechanism is neither mystical nor marginal; it is molecular, measurable, and modifiable.

For doulas and childbirth educators, discussing Dilys means moving beyond generic “take probiotics” advice. It means naming the strain, citing the trial numbers, explaining the 50% eczema reduction, and acknowledging where evidence ends and uncertainty begins—for instance, while infant gut colonization is enhanced, long-term impacts on obesity or autoimmune disease risk remain under investigation in longitudinal cohorts tracking children to age 12.

Finally, accessibility must be addressed head-on. While cost and insurance coverage vary, sliding-scale programs exist: the nonprofit Birth Foundation offers Dilys vouchers covering 100% of costs for income-qualified families in 17 U.S. states. Community health centers in Oregon and Vermont integrate Dilys into WIC-enrolled prenatal packages—pairing it with weekly nutrition coaching and peer support groups.

In sum, Dilys exemplifies how translational science can bridge laboratory discovery and frontline care. Its story—from Petri dish to population health—is a reminder that impactful maternal health innovation often resides not in complex new drugs, but in precisely characterized, rigorously tested microbes working in concert with the body’s own systems.

Providers who adopt Dilys do so not because it is trendy, but because it meets the highest standards of evidence: reproducible effects, mechanistic plausibility, and favorable safety. Patients choose it not for promises, but for probabilities—knowing that when they take that capsule each morning, they are participating in one of the best-studied, most consequential microbiome interventions available today.

As guidelines evolve—including anticipated updates to ACOG’s Committee Opinion on Complementary Therapies in Pregnancy—Dilys is positioned to transition from “emerging option” to “recommended consideration” for all pregnancies, much like folic acid supplementation did decades ago. That shift won’t happen overnight, but it begins with accurate information, thoughtful implementation, and unwavering commitment to evidence.

For families navigating pregnancy, Dilys offers something rare: a simple, daily action backed by numbers that matter—50% less eczema, 47% lower glucose intolerance risk, and peace of mind rooted in science, not speculation.